Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3 results about "Schizoaffective disorder" patented technology

A mental disorder in which a person experiences a combination of schizophrenia and mood disorder symptoms.

Injectable formulations of multicyclic antidepressants

PendingAU2024410717A1DiseaseSchizo-affective type
The invention relates to a composition comprising a piperazine-benzazepine, a buffer and a surfactant, and uses of such compositions such as treating, preventing, and / or suppressing symptoms of schizophrenia, schizoaffective disorders, and / or Parkinson's disease. The compositions have improved parameters such as a lower variance in pH, improved stability during storage, and lower solubility of piperazine-benzazepines, resulting in piperazine-benzazepine particle formation with improved particle size and particle size distribution. The compositions are useful as therapeutic agent, for instance through parenteral administration to a subject.
Owner:CLOZATHERA BV

Anti-psychotic composition and treatment methods

Provided herein are methods of treatment of psychiatric disorders requiring treatment with an antipsychotic drug, such as schizophrenia or schizoaffective disorder, comprising administration of both the antipsychotic drug and a W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof to treat symptoms of the psychiatric disorder. Treatment is typically continued for at least four weeks. A combination dosage form comprising both the antipsychotic drug and the W. somnifera plant part, extract, chemical constituent(s) thereof, or a derivative thereof in amounts effective to treat the psychiatric disorder.
Owner:UNIV OF PITTSBURGH OF THE COMMONWEALTH SYST OF HIGHER EDUCATION

Use of idalpir as monotherapy or in combination with antipsychotic agents to treat mental or neurological disorders in patients with significant loss of pleasure

The present invention relates to the treatment of psychiatric or neurological disorders in patients in need of pleasant sensation (lack of pleasure or pursuit of incentive activities) by administering idarsone or a pharmaceutically acceptable salt thereof as a monotherapy or in combination with an antipsychotic agent. Examples of such psychiatric or neurological disorders include major depressive disorder, bipolar depression (such as bipolar type I or bipolar type II disorder), post-traumatic stress disorder, substance use disorder, pleasant sensation loss related aspects of schizophrenia (e.g., negative symptoms), and split affective disorder (e.g., with emotional and / or negative symptoms).
Owner:OPTO NEUROSCIENCE INC